Novo Nordisk, Sanofi, and Lilly are three key vendors highlighted in a new Technavio report
London, 24 August 2015 – Technavio has published a new report on the global human insulin market, which is expected to grow at a CAGR of over 10% from 2015-2019.
Human insulin market segmentation including type of insulin, type of disease and geography
Technavio’s report analyses the solutions and products offered by market vendors and presents a comprehensive breakdown in terms of market segmentation for different types of insulin, including fast-acting insulin, intermediate-acting insulin, and long-acting insulin.
Additionally, analysts have segmented market projections by key geography, and also by different types of disease, focusing on type 1 diabetes and type 2 diabetes.
“Key players in the market are extending their support to academic institutions for R&D of innovative products for diabetes care. For instance, Sanofi Diabetes collaborated with academic institutions such as Helmholtz Zentrum and Charite to support R&D in the diabetes care segment. Such collaborations enable the incorporation of research expertise of academic institutions with the marketing intelligence of pharma companies, which is expected to support the growth of the market,” says Faisal Ghaus, Vice President of Technavio.
Human insulin: Market scope and calculation of market size
This report covers the present scenario and growth prospects for the global human insulin market from 2015-2019. To calculate the market size, we have used the revenue generated from the sales of drugs, by three major vendors, to treat the following diseases.
- Type 1 diabetes
- Type 2 diabetes
Industry analysis includes:
- Novo Nordisk
Market Growth Drivers:
- Increase in prevalence of diabetes
- Rise in obesity
- Stringent regulatory environment
- Low diagnosis rate
- Increase in R&D for novel mechanisms
- Rise in awareness programs
View the global human insulin market report.